Subscribe to Search results

Inquiry publishes timetable for evidence relevant to potential recommendations

Published on:

Further details on the preliminary hearings

Published on:

In the SNBTS Annual Report 1992-1993 it was stated that a new Aberdeen RTC was not due to open until 1993.

Published on:

The Medicines Inspectorate report on the RTC in Edinburgh described the facilities for the processing and handling of blood as grossly deficient.

Published on:

A report prepared by the Scottish National Blood Transfusion Service stated that RTCs were initially not thought to be entitled to Crown Immunity when the Medicines Act came into force.

Published on:

Scottish RTCs subjected themselves to formal inspections from the Medicines Inspectors to obtain manufacturing licences. Inspections started in January 1980 and all centres had been inspected by March 1982.

Published on:

The first external inspection of the RTC in Belfast was a visit by the Protein Fractionation Centre.

Published on:

South East Thames RTC kept a quarter of product received from BPL for emergencies, and the remaining product was distributed to haemophilia centres in the area in proportion to the number of people with bleeding disorders treated at the centres.

Published on:

The North London RTC used Dr Simon Ardeman, a consultant haematologist at Edgware General Hospital, to act as the arbitrator between the various hospitals which received their Factor 8 from the North London RTC, to determine their allocation of Factor 8.

Published on:

In a letter Dr Jean Harrison explained the situation with regard to charges for Factor 8. The situation prior to 1 April 1989 was that haemophilia centres were charged for any supply of Factor 8 by BPL above their free allocation.

Published on:

The North East Thames RTC (Brentwood) ceased to act as a wholesaler for BPL products.

Published on:

In his letter to Dr William Maycock, Dr Jack Darnborough rejected the idea of distributing Factor 8 on a supra-regional basis and of RTCs distributing commercial Factor 8 as well as NHS Factor 8 and cryoprecipitate.

Published on:

Dr Jack Darnborough agreed to organise the purchase and distribution of commercial Factor 8. He noted one of the reasons for his change of mind as being his knowledge that a haematologist in his region had been purchasing large quantities of commercial Factor 8, costing between £8,000 and £10,000 a year.

Published on:

Dr William Maycock convinced Dr Jack Darnborough of the advantages of distributing commercial Factor 8.

Published on:

Barry Barber, sales manager at Cutter Laboratories, informed Dr Jack Darnborough (Cambridge RTC), about a request to tender for the next Factor 8 contract.

Published on:

Dr Jack Darnborough (Director, East Anglian Blood Transfusion Centre) met with a representative from Cutter Laboratories to discuss the supply of Koate.

Published on:

The Yorkshire RTC did not purchase, store or distribute commercial Factor 8 prior to 1981, but discussions were had with the Regional Health Authority around July 1981 regarding future policy in this matter.

Published on:

The Yorkshire RTC adopted regional purchase of all blood products.

Published on:

The Yorkshire RTC began centrally purchasing Factor 8 on behalf of haemophilia units in Yorkshire based on their individual requests.

Published on:

By January 1981, the West Midlands RTC had established the practice of holding and issuing all Factor 8 products.

Published on: